Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

GEFITINIB for Lung adenocarcinoma stage iv: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 140 adverse event reports in the FDA FAERS database where GEFITINIB was used for Lung adenocarcinoma stage iv.

Most Reported Side Effects for GEFITINIB

Side Effect Reports % Deaths Hosp.
Malignant neoplasm progression 1,651 35.2% 217 160
Drug resistance 1,228 26.1% 95 115
Death 590 12.6% 589 50
Diarrhoea 393 8.4% 73 114
Rash 318 6.8% 48 66
Metastases to central nervous system 306 6.5% 51 49
Acquired gene mutation 250 5.3% 36 21
Disease progression 244 5.2% 33 16
Drug ineffective 197 4.2% 33 39
Off label use 166 3.5% 37 40
Decreased appetite 163 3.5% 44 55
Metastases to bone 147 3.1% 19 14
Nausea 139 3.0% 24 41
Pleural effusion 137 2.9% 34 52
Fatigue 129 2.8% 31 28

Other Indications for GEFITINIB

Non-small cell lung cancer (1,786) Lung neoplasm malignant (779) Lung adenocarcinoma (556) Egfr gene mutation (97) Non-small cell lung cancer metastatic (94) Product used for unknown indication (85) Non-small cell lung cancer stage iv (82) Lung carcinoma cell type unspecified stage 0 (75) Neoplasm malignant (53) Adenocarcinoma (43)

Other Drugs Used for Lung adenocarcinoma stage iv

PEMBROLIZUMAB (1,644) PEMETREXED (1,510) CARBOPLATIN (1,138) CISPLATIN (303) OSIMERTINIB (278) PACLITAXEL (223) BEVACIZUMAB (213) ERLOTINIB (203) DOCETAXEL (188) CRIZOTINIB (164)

Related Pages

GEFITINIB Full Profile All Lung adenocarcinoma stage iv Drugs GEFITINIB Demographics GEFITINIB Timeline